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“Simplicity is complexity resolved”—Constantin Brancusi
Postoperative whole breast radiation therapy (WBRT) after 
breast conserving surgery (BCS) is considered the standard 
of care for early-stage breast cancer (EBC) patients. In 
recent population-based studies long-term overall survival 
(OS) might even be better than that following mastectomy 
without radiotherapy (RT) (1,2). Overall, WBRT halves 
the 10-year rate of any breast cancer recurrence and 
reduces by about one sixth the 15-year breast cancer-related 
mortality (3). Nevertheless, the absolute reduction in the 
rate of relapse and cancer mortality are to some extent 
proportionally affected by patient- and tumor-related 
characteristics including age, grade, nodal involvement and 
estrogen receptor status, calling for the need of tailoring 
clinical indications for WBRT (3). 
Killander et al. recently reported the long-term results of 
the SweBCG 91 RT randomized phase III trial, investigating 
the option to omit WBRT for selected EBC (4). Clinical 
T1–T2N0M0 patients were randomly assigned to receive 
or not WBRT (48–54 Gy in 24–27 fractions) after BCS. 
Adjuvant systemic therapy was prescribed for stage II 
patients according to regional treatment guidelines. Among 
the 1,187 randomized patients, only 84 received tamoxifen 
(47 vs. 37 in the control and RT arms, respectively) and 22 
CMF chemotherapy (13 vs. 9) (4). After a median follow-
up of 15.6 years, patients without WBRT had a significantly 
higher ipsilateral breast tumor recurrence risk (IBTR) 
(23.9%), compared to irradiated patients (11.5%) and a 
lower recurrence-free survival (51.7% vs. 60.4%). OS did not 
significantly differ (68.4% vs. 71.1%) (4). 
The role of WBRT after BCS has been extensively 
documented in several historical randomized studies, 
carried out both in Europe and in the USA, showing a 
significant increase in IBTR rates for patients not receiving 
RT (5-9). Local relapses at 5 years were observed to rise 
from 2–20% with WBRT to 27–42% without. However, 
none of these trials, including SweBCG 91 RT, were able 
to demonstrate an OS benefit by the addition of WBRT. 
Moreover, the observation that certain subsets of patients 
may have a lower risk of IBTR according to specific 
tumor- and patient-related characteristics, led to initiatives 
to selectively decrease the overall therapeutic burden in 
tailored subgroups of EBC (10). As for example in the Milan 
III trial, the IBTR rates in the no WBRT group were 7.4% 
at 10 years below 45 years of age, 3.1% in the age range 
46–55 years, 1.7% for 56–65 years and equal to the WBRT 
arm over 65 years, age was often used as the most important 
discriminating factor (11). 
Ideally, individualized cancer therapy should allow 
for treatment option selection according to clinical as 
well as biological characteristics, favoring the minimally 
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required therapeutic package to achieve adequate tumor 
control with acceptable toxicity and optimal long-term 
quality of life (12). This is particularly topical in “low-
risk” breast cancer patients. Therefore, several studies 
investigated the potentials of de-intensification of treatment 
in this subgroup. In the CALGB 9343 trial, women aged 
≥70 years with estrogen-receptor positive and clinical stage 
I (cT1N0M0) disease were randomized to receive WBRT 
+ tamoxifen or exclusive tamoxifen as adjuvant treatment 
after BCS. Multiple endpoints were investigated (time to 
local and regional recurrence, rate of salvage mastectomies, 
time to distant failure and breast cancer-specific and OS). 
At 5 years, the IBTR rate was higher for patients having 
WBRT omitted (4% vs. 1%), while all other endpoints were 
not significantly different. The arm submitted to tamoxifen 
alone had better cosmetic outcomes and lower adverse 
effects (13). Similar findings were observed in the PRIME II 
study, where low-risk EBC patients aged 65 years or older 
[positive hormone receptors; axillary node negative; clinical 
T1–T2 disease up to 3 cm, grade 3 or lymphovascular 
invasion (LVI) but not both, and clear margins after BCS] 
and receiving adjuvant endocrine therapy were randomized 
to conventionally fractionated or hypofractionated WBRT 
vs. no radiation (14). The rates of IBTR were 1.3% for 
WBRT and 4.1% for the no radiation arm at 5 years, with 
a global hazard ratio (HR) of 5.19. Regional, distant and 
contralateral breast relapses and breast cancer-related 
mortality were not different. An Italian study, with similar 
design and a 9-year median observation time, found similar 
rates of IBTR (3.4 for WBRT vs. 4.4 for no radiation) and 
OS (81.4% vs. 83.7%) in unifocal breast cancer <25 mm, 
with 0–3 positive axillary nodes and no extensive intraductal 
component or LVI (15). 
Notwithstanding these studies, the identification of 
the most appropriate EBC category to be offered de-
intensification with WBRT omission remains a challenge. 
This is confirmed by the data reported in the SweBCG 
91 RT trial, where the 15-year cumulative incidence of 
IBTR in patients without WBRT ranged from 16.7% to 
28% among subgroups within different categories based 
on age, tumor size, hormonal receptor status and method 
of diagnosis (4). More interestingly, in low-risk patients 
(>64 years, <21 mm sized tumor, positive oestrogen and 
progesterone receptor) the cumulative reduction in IBTR 
rates following WBRT was even higher than in the whole 
population (IBRT: 25.9% for no WBRT arm vs. 5.3% for 
the radiation arm). The explanation why no influence of 
the omission of WBRT on OS was detected might be that 
follow-up is still too short, the low intensity of adjuvant 
systemic therapy given initially and/or the effectiveness of 
salvage therapy after BCS alone. Moreover, elderly low-risk 
EBC form a particular population with a high burden of 
competing causes of death. However, in general, preventing 
a local relapse has clinical meaningfulness (3) and there is a 
need for a careful clinical decision-making process before 
omitting WBRT, even in low-risk EBC and even without 
demonstration of a clear impact of WBRT on OS in this 
setting. 
The importance of endocrine therapy in patients having 
WBRT omitted was shown in the German Breast Study 
Group (GBSG) trial, where the crude risk of local recurrence 
at 10 years was 7–10% in patients treated either with BCS 
and WBRT, BCS and tamoxifen, or BCS and both, but 
was 34% in those treated with BCS alone (16). However, 
as treatment safety and quality of life are also crucial 
endpoints, we should also question the need for adjuvant 
systemic therapy in low-risk EBC. Endocrine therapy 
may be associated with an increased risk for osteoporosis 
with skeletal related events, cardiovascular disease, 
sexual dysfunction and even neurocognitive effects (10). 
Moreover the impact of hormonal therapy in terms of 
OS in post-menopausal patients has yet to be confirmed 
with even compliance to treatment being challenging, as 
only 35–60% of women accomplish a full 5-year adjuvant 
program (10). Overall, the side-effects of adjuvant systemic 
therapy are expected to outweigh those of WBRT, especially 
as new developments in the field of radiation oncology 
substantially decreased the burden of radiation therapy (10). 
Hypofractionated schedules of WBRT and accelerated 
partial breast irradiation provide new options to decrease 
overall treatment time, cost, inconvenience, and toxicity of 
postoperative radiation (17-19). 
The results of the SweBCG 91 RT trial and others 
confirm that clinical and pathologic selection of seemingly 
low-risk features like age for omission of radiation have 
reached their limit of usefulness. A selection based on 
biology of the tumor may be more fruitful in the future. 
Liu et al. conducted a retrospective subgroup analysis 
on 501 of 769 available blocks from the larger Canadian 
prospective trial that had shown a significant benefit to 
WBRT after BCS and tamoxifen (20). They conducted 
intrinsic subtyping and showed that luminal subtypes 
seemed to derive less benefit from WBRT (luminal A 
HR: 0.40; luminal B HR: 0.51) than high-risk subtypes 
of HER-2 or triple negative (HR: 0.13), however without 
reaching statistical significance. Additional studies in North 
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America and Europe that will study the use of subtyping for 
EBC in clinically low-risk women by receptor expression, 
genomic expression or signature assays to study omission of 
radiation include the LUMINA, IDEA, PRECISION and 
PRIMITIME trials (21).
Conclusion: the selection of the most appropriate 
treatment for low-risk breast cancer patients should take 
into account not only risk for local relapse or impact on 
survival, but also the treatment-related toxicity profile, 
patient quality of life, psycho-social issues and cost-
effectiveness. Biological and molecular patterns should 
be investigated to assist in the clinical decision-making 
process. Composite endpoints and validated evaluation tools 
are mandatory for comparative evaluation of treatments 
and appropriate allocation of future patients. The quest 
to identify which EBC patients can forego WBRT after 
BCS remains to be accomplished. Simple questions may 
lead to complicated answers but using a holistic approach 
on therapeutic modalities and clinical endpoints we may 
achieve simplicity through a resolution of complexity, with 
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